Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858235 | 0.89 | SMN1; SMN2 (0.42) | PPARGSMN1; SMN2KMT2AGAAMEN1 | |
| SCHEMBL6862542 | 0.84 | MTNR1A (0.43) | PPARGSMN1; SMN2MTNR1AMTNR1BCYP17A1 | |
| SCHEMBL6865527 | 0.79 | ALDH1A1 (0.39) | ALDH1A1GAACA12CA1CA9 | |
| SCHEMBL6858246 | 0.71 | SMN1; SMN2 (0.46) | PPARGSMN1; SMN2KMT2AALDH1A1GAA | |
| SCHEMBL31041194 | 0.71 | PTGER1 (0.33) | KMT2AALDH1A1MEN1 | |
| SCHEMBL6862641 | 0.69 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2AALDH1A1GAAMEN1 | |
| SCHEMBL6863345 | 0.69 | THRB (0.44) | PPARGMTNR1AMTNR1BCYP17A1ALDH1A1 | |
| SCHEMBL18467344 | 0.68 | ALDH1A1 (0.58) | PPARGSMN1; SMN2CYP17A1ALDH1A1GAA | |
| SCHEMBL6903617 | 0.67 | MAPT (0.52) | SMN1; SMN2KMT2AALDH1A1GAAMEN1 | |
| SCHEMBL22548789 | 0.67 | CYP17A1 (0.51) | SMN1; SMN2CYP17A1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | PPARG 217/4885SMN1; SMN2 4560/4885MTNR1A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.